- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07777471
Improving Delivery of Aging-Related Supportive Care for Older Adults With Acute Myeloid Leukemia (ACTIVE DEFAULT)
Active Default Pilot: Implementation of Geriatric Assessment-Driven Supportive Care for Older Adults With Acute Myeloid Leukemia Receiving Venetoclax-Based Therapy
The goal of this clinical trial is to test a way of delivering supportive care to adults 60 years and older who are starting venetoclax-based treatment for newly diagnosed acute myeloid leukemia (AML). Older adults with AML often have aging-related needs, such as problems with mobility, nutrition, mood, memory, or medications, that are not always addressed in a consistent way. In this study, a health questionnaire and short in-person checks (a geriatric assessment) are used to find these needs early, and matching supportive care orders are prepared in the electronic health record and sent to the treating doctor, who decides whether to place each one. This approach is called Active Default. The main questions the study aims to answer are:
- How often are the prepared supportive care orders signed by treating doctors (implementation fidelity)?
- Can each step of the process, from completing the assessment to receiving supportive care services, be carried out as planned?
Participants will:
- Complete questionnaires and short in-person checks of walking, balance, strength, memory, mood, and medications at the start of treatment
- Receive supportive care services (for example physical therapy, nutrition, or social work) if their doctor approves the prepared orders
- Answer phone check-ins over 90 days and repeat two short checks at about two months
- Be invited to one optional interview about their experience
Healthcare providers involved in participants' care will be invited to complete a one-time survey and an optional interview about the approach.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Aditi Sharma, MD
- Número de telefone: 205-975-0412
- E-mail: adshar@uabmc.edu
Locais de estudo
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35233
- University of Alabama at Birmingham
-
Subinvestigador:
- Nicole Henderson, PhD
-
Contato:
- Aditi Sharma, MD
- Número de telefone: 205-975-0412
- E-mail: adshar@uabmc.edu
-
Investigador principal:
- Aditi Sharma, MD
-
Subinvestigador:
- Gabrielle Rocque, MD, MSPH
-
Subinvestigador:
- Smita Bhatia, MD, MPH
-
Subinvestigador:
- Pankit Vachhani, MD
-
Subinvestigador:
- Andres Azuero, PhD, MBA
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
Patient participants:
- Age 60 years or older
- Newly diagnosed acute myeloid leukemia (AML), including de novo, secondary, or therapy-related AML, per current World Health Organization (WHO) or International Consensus Classification (ICC) classification
- Planned for first-line venetoclax-based lower-intensity therapy
- English-speaking
- Able to provide informed consent personally or through a Legally Authorized Representative (LAR)
Provider participants:
-Participating leukemia attending physicians and supportive care service leads involved in the care of enrolled participants
Exclusion Criteria:
Patient participants:
- Acute promyelocytic leukemia
- Planned intensive induction or non-venetoclax-based therapy
- Life expectancy under 14 days or hospice enrollment at screening
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Pesquisa de serviços de saúde
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Active Default
Patients aged 60 and older with newly diagnosed AML starting venetoclax-based therapy (n=25) receive the Active Default intervention: a geriatric assessment at the start of treatment, with results crossing pre-specified thresholds generating matched supportive care orders that are prepared in the electronic health record and sent to the treating physician to approve or decline.
Patients are followed for 90 days, with phone check-ins and repeat physical function and cognition checks at about 60 days.
Healthcare providers involved in enrolled patients' care (up to 15) complete a one-time survey and are invited to an optional interview about the approach.
|
An electronic health record-based order-queuing mechanism that delivers geriatric assessment-driven supportive care.
A structured geriatric assessment is completed at the start of venetoclax-based therapy.
Results crossing pre-specified thresholds trigger matched supportive care orders (for example physical therapy, nutrition, social work, pharmacy medication review, geriatrics, mental health, chaplaincy), which the study team prepares as proposed orders for the treating physician to approve or decline.
The supportive care services themselves are standard of care; the intervention modifies only the order-entry workflow.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Proportion of eligible triggered supportive care orders signed by the treating physician within 7 days (implementation fidelity)
Prazo: Within 7 days of each supportive care order placement; orders are placed after the baseline geriatric assessment and within 7 days before or after Cycle 1 Day 1 of venetoclax-based therapy (each cycle is 28 days)
|
Measured as the number of eligible geriatric assessment-triggered supportive care orders signed by the treating physician within 7 days of order placement, divided by the total number of eligible triggered orders, using electronic health record order data.
Eligible triggers are those not already engaged in the corresponding service or pre-declined by the patient at the pre-referral screen.
Reported as a point estimate with 95% Clopper-Pearson confidence interval.
|
Within 7 days of each supportive care order placement; orders are placed after the baseline geriatric assessment and within 7 days before or after Cycle 1 Day 1 of venetoclax-based therapy (each cycle is 28 days)
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Proportion of signed supportive care orders with at least one completed service visit (service engagement)
Prazo: 90 days from Cycle 1 Day 1, the first day of venetoclax-based therapy (each cycle is 28 days)
|
Measured as the number of signed supportive care orders with at least one completed visit in the corresponding service within 90 days of Cycle 1 Day 1, divided by the total number of signed orders, using electronic health record data.
Reported as a point estimate with 95% Clopper-Pearson confidence interval.
|
90 days from Cycle 1 Day 1, the first day of venetoclax-based therapy (each cycle is 28 days)
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Aditi Sharma, MD, University of Alabama at Birmingham
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- IRB-300016966
- UAB (Outro identificador: UAB)
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .